trending Market Intelligence /marketintelligence/en/news-insights/trending/ldpSCBHyByPPQsP0HYqdtg2 content esgSubNav
In This List

Akcea appoints 3 directors day after announcing IPO

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Akcea appoints 3 directors day after announcing IPO

Ionis Pharmaceuticals Inc. subsidiary Akcea Therapeutics Inc. named three new independent directors. The board will initially consist of six members.

Christopher Gabrieli will serve as chairman of the board whereas Elaine Hochberg and Sandford Smith will serve as board members.

Gabrieli, who previously served on the Ionis board, is partner emeritus at Bessemer Venture Partners. Hochberg is the former chief commercial officer of Forest Laboratories Inc. whereas Smith is the founder and chairman of Global Biolink Partners.

The three remaining board positions are held by Stanley Crooke, chairman and CEO of Ionis; B. Lynne Parshall, COO of Ionis; and Paula Soteropoulos, president and CEO of Akcea.

Akcea recently announced a $100 million initial public offering.